Apr 26

Donezepil is a cholinesterase inhibitor of the M2 variety.

Read the rest of this entry »

Apr 24

An antagonist of NMDA receptors and a potassium channel blocker make an appearance in Germany.

Read the rest of this entry »

Apr 22

Although one of the recent “golden boys” of neuropathic pain treatment, with many endorsements from pain clinics, lamotrigine is not proving out.

Read the rest of this entry »

Apr 10

Often misread by neurologists as mere spasticity, the heightened flexor response has been noted in the surveys, but not reported in the literature until now.

Read the rest of this entry »

Apr 10

New results suggest caution in long term use of ketamine. It also raises the question of whether ketamine might be exploited to suppress sprouts at the cut ends of interrupted nerve fibers, which sprouts promote hypersensitization.

Read the rest of this entry »

Apr 9

Confessions of Central Pain.

Read the rest of this entry »

Apr 3

Short tech article

Read the rest of this entry »

Apr 3

We are deliberately trying to keep these technical articles short for ease in reading, but that does not mean they are not important to you.

Read the rest of this entry »

Apr 3

This is part II of our noting of anticancer steps that should have benefit for nerve injury pain. The work is preliminary at this point, not in human trials for pain.

Read the rest of this entry »

Apr 3
Enzastaurin
icon1 Kevin | icon2 Uncategorized | icon4 04 3rd, 2007| icon3No Comments »

We have said before that given the much larger amount of money available to cancer and heart disease, and due to the recently recognized link with inflammation in these conditions, that central pain might well be cured as a spinoff. Here is a new drug that stops Protein Kinase C.

Read the rest of this entry »

« Previous Entries